Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio, total revenue increased 42$1.07 on a reported basis and $1.18 on a non-GAAP basis, both inclusive of$3.08 of acquired IPR&D charges. 2024 revenue guidance range updated to $45.4 to$46.0 b ...